Company intelligence / Profile preview

NextGen Invitro Diagnostics

Ownership: Private
Development stage: Commercial

Overview

NextGen Invitro Diagnostics has developed and commercialized multiplexed molecular diagnostics for infectious diseases such as tuberculosis and leishmaniasis. Their TB test has received grants from BIRAC and USISTEF. The company is focused on affordable, accessible point-of-care testing with clinical validation in India and abroad. They have also licensed LAMP technology for leishmaniasis diagnosis from ICMR.

Therapeutic areas: Infectious Diseases
Modalities: DeviceMolecular diagnostic kitELISA kitRT-PCR kitMagnetic bead-based nucleic acid isolation kitsSpin column-based nucleic acid isolation kits
Industry: Molecular Diagnostics

Partnerships

BIRAC (Biotechnology Innovation and Research Assistant Council)USISTEF (United States–India Science & Technology Endowment Fund)Indian Council of Medical Research (ICMR) – licensee relationship for LAMP technologyPremas Biotech

Beyond the preview

Go deeper on NextGen Invitro Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NextGen Invitro Diagnostics.

Explore the full profile